MBRX
Moleculin BiotechFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
10
U.S. public peers
Grade Position
Below peers
vs peer average
MBRX vs peer average
29/100
MBRX vs. peer average (F vs. D)
Grade spread
B 3 · C 1 · D 2 · F 4
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
FDMT is the first available peer comparator.
Specialty oncology/biotech with niche drug candidates; parallels in development-stage valuation dynamics.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
MBRX
Moleculin Biotech
FDMT
4D Molecular Therapeutics
Grade
F
F
Momentum
67
44
Value
41
41
Sentiment
0
0
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Defensive
Defensive
Grade position vs FDMT
MBRX / FDMT
Grade Position
Below peers
MBRX vs. peer average (F vs. D)
29/100
Momentum
67
MBRXValue
41
MBRXSentiment
0
MBRXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs MBRX
FDMT is the first peer returned for this comparison set.